NCT07557706 Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease
| NCT ID | NCT07557706 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Alabama at Birmingham |
| Condition | PARKINSON DISEASE (Disorder) |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-09-15 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-09-15 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of idiopathic PD * Stable medication for at least 4 weeks prior to the study Exclusion Criteria: * Use of beta blockers * Sustained severe hypertension (\>/= 180/110 mmHg while seated) * Significant uncontrolled cardiac arrhythmia * Unstable angina * Congestive heart failure * History of myocardial infarction * History of seizures * Severe cognitive impairment * Pregnant women or women who are planning to become pregnant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07557706 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07557706 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07557706 currently recruiting?
Yes, NCT07557706 is actively recruiting participants. Contact the research team at amelgin@uab.edu for enrollment information.
Where is the NCT07557706 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT07557706 clinical trial?
NCT07557706 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.